These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1895 related articles for article (PubMed ID: 28639415)

  • 21. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis.
    Pham B; Thomas SM; Lillie E; Lee T; Hamid J; Richter T; Janoudi G; Agarwal A; Sharpe JP; Scott A; Warren R; Brahmbhatt R; Macdonald E; Straus SE; Tricco AC
    BMJ Open; 2019 May; 9(5):e022031. PubMed ID: 31142516
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Standard threshold laser versus subthreshold micropulse laser for adults with diabetic macular oedema: the DIAMONDS non-inferiority RCT.
    Lois N; Campbell C; Waugh N; Azuara-Blanco A; Maredza M; Mistry H; McAuley D; Acharya N; Aslam TM; Bailey C; Chong V; Downey L; Eleftheriadis H; Fatum S; George S; Ghanchi F; Groppe M; Hamilton R; Menon G; Saad A; Sivaprasad S; Shiew M; Steel DH; Talks JS; Doherty P; McDowell C; Clarke M
    Health Technol Assess; 2022 Dec; 26(50):1-86. PubMed ID: 36541393
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.
    Martinez-Zapata MJ; Salvador I; Martí-Carvajal AJ; Pijoan JI; Cordero JA; Ponomarev D; Kernohan A; Solà I; Virgili G
    Cochrane Database Syst Rev; 2023 Mar; 3(3):CD008721. PubMed ID: 36939655
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravitreal ranibizumab versus aflibercept versus bevacizumab for macular oedema due to central retinal vein occlusion: the LEAVO non-inferiority three-arm RCT.
    Hykin P; Prevost AT; Sivaprasad S; Vasconcelos JC; Murphy C; Kelly J; Ramu J; Alshreef A; Flight L; Pennington R; Hounsome B; Lever E; Metry A; Poku E; Yang Y; Harding SP; Lotery A; Chakravarthy U; Brazier J
    Health Technol Assess; 2021 Jun; 25(38):1-196. PubMed ID: 34132192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An efficacy comparison of anti-vascular growth factor agents and laser photocoagulation in diabetic macular edema: a network meta-analysis incorporating individual patient-level data.
    Muston D; Korobelnik JF; Reason T; Hawkins N; Chatzitheofilou I; Ryan F; Kaiser PK
    BMC Ophthalmol; 2018 Dec; 18(1):340. PubMed ID: 30591022
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aflibercept, bevacizumab or ranibizumab for diabetic macular oedema: recent clinically relevant findings from DRCR.net Protocol T.
    Cai S; Bressler NM
    Curr Opin Ophthalmol; 2017 Nov; 28(6):636-643. PubMed ID: 28837425
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema: Two-Year Results from a Comparative Effectiveness Randomized Clinical Trial.
    Wells JA; Glassman AR; Ayala AR; Jampol LM; Bressler NM; Bressler SB; Brucker AJ; Ferris FL; Hampton GR; Jhaveri C; Melia M; Beck RW;
    Ophthalmology; 2016 Jun; 123(6):1351-9. PubMed ID: 26935357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiotherapy for neovascular age-related macular degeneration.
    Evans JR; Igwe C; Jackson TL; Chong V
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD004004. PubMed ID: 32844399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Interventions for central serous chorioretinopathy: a network meta-analysis.
    Salehi M; Wenick AS; Law HA; Evans JR; Gehlbach P
    Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD011841. PubMed ID: 26691378
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association of Baseline Visual Acuity and Retinal Thickness With 1-Year Efficacy of Aflibercept, Bevacizumab, and Ranibizumab for Diabetic Macular Edema.
    Wells JA; Glassman AR; Jampol LM; Aiello LP; Antoszyk AN; Baker CW; Bressler NM; Browning DJ; Connor CG; Elman MJ; Ferris FL; Friedman SM; Melia M; Pieramici DJ; Sun JK; Beck RW;
    JAMA Ophthalmol; 2016 Feb; 134(2):127-34. PubMed ID: 26605836
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of the efficacy and safety of drug therapies for macular edema secondary to central retinal vein occlusion.
    Qian T; Zhao M; Wan Y; Li M; Xu X
    BMJ Open; 2018 Dec; 8(12):e022700. PubMed ID: 30593547
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice.
    Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA;
    JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials.
    Chaudhary V; Sarohia GS; Phillips MR; Park D; Xie J; Zeraatkar D; Fung M; Thabane L; Loewenstein A; Holz FG; Garg SJ; Kaiser PK; Bhandari M; Guymer RH; Fraser-Bell S; Sivaprasad S; Wykoff CC
    Eye (Lond); 2023 Jul; 37(10):1966-1974. PubMed ID: 36369263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Laser photocoagulation for proliferative diabetic retinopathy.
    Evans JR; Michelessi M; Virgili G
    Cochrane Database Syst Rev; 2014 Nov; 2014(11):CD011234. PubMed ID: 25420029
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative effectiveness of anti-VEGF agents for diabetic macular edema.
    Ollendorf DA; Colby JA; Pearson SD
    Int J Technol Assess Health Care; 2013 Oct; 29(4):392-401. PubMed ID: 24290332
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab.
    Spooner K; Fraser-Bell S; Hong T; Chang A
    Clin Exp Ophthalmol; 2020 Jan; 48(1):53-60. PubMed ID: 31498950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Five-Year Outcomes after Initial Aflibercept, Bevacizumab, or Ranibizumab Treatment for Diabetic Macular Edema (Protocol T Extension Study).
    Glassman AR; Wells JA; Josic K; Maguire MG; Antoszyk AN; Baker C; Beaulieu WT; Elman MJ; Jampol LM; Sun JK
    Ophthalmology; 2020 Sep; 127(9):1201-1210. PubMed ID: 32402554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-Vascular Endothelial Growth Factor Comparative Effectiveness Trial for Diabetic Macular Edema: Additional Efficacy Post Hoc Analyses of a Randomized Clinical Trial.
    Jampol LM; Glassman AR; Bressler NM; Wells JA; Ayala AR;
    JAMA Ophthalmol; 2016 Dec; 134(12):. PubMed ID: 27711918
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 95.